Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Rhea-AI Summary

Nascent Biotech (OTCQB:NBIO) has completed the third cohort in its Phase I clinical trial for Brain Cancer, advancing toward the fourth and potentially final cohort. Although the third cohort took longer than expected, the data is deemed useful for future directions. Patient enrollment is ongoing, and the company plans to conduct pharmacokinetic studies to assess the need for a fifth cohort. Pritumumab (PTB) is a targeted immunotherapy designed to selectively target cancer cells without harming healthy cells, marking a significant advancement in cancer treatment.

Positive

• Completion of the third cohort in Phase I trial for brain cancer.
• Advancement to the fourth cohort signals progress in clinical development.
• Continued patient enrollment and potential for future cohorts indicates ongoing research and commitment.

Negative

• The third cohort took longer than anticipated, suggesting possible delays in the trial timeline.

VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of the Third cohort in dosing patients for its Phase I trial for Brain Cancer. After reviewing the data gathered from the first three cohorts, this milestone will allow the trial to advance to the fourth and possibly final cohort.

Patient enrollment will continue for Phase I. Anyone interested may review trial requirements at www.clinicaltrials.gov, then search Pritumumab.

"Having completed the first three cohorts, we are excited to move to our fourth and possibly final cohort in the Phase I trial. The third cohort took longer than expected but the data received is very useful moving forward," noted Nascent CEO, Sean Carrick, further stating that, as the fourth cohort is underway, Nascent will also be performing PK studies to help determine if a fifth cohort is needed.

PTB is a natural human antibody that works by binding to Cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy unlike chemotherapy targets only cancer cells without damaging healthy cells.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick | President | CEO | Nascent Biotech, Inc.
772.713.0541 Cell | sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media
(800) 301-7883

SOURCE: Nascent Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/704085/Nascent-Biotech-Completes-Third-Cohort-in-Phase-1-Human-Trial-for-Primary-and-Metastatic-Brain-Cancer

FAQ

What is the purpose of Nascent Biotech's Phase I trial for brain cancer?

The Phase I trial aims to evaluate the safety and efficacy of Pritumumab (PTB) as a targeted immunotherapy for brain cancer.

What results have been reported from the Phase I trial for NBIO?

The trial has successfully completed the first three cohorts, with data indicating progress towards the fourth cohort.

What does the completion of the third cohort mean for NBIO's clinical trial?

Completing the third cohort allows the trial to advance, potentially leading to a final cohort and further evaluation of Pritumumab.

Are there any plans for a fifth cohort in the NBIO trial?

Yes, pharmacokinetic studies will determine if a fifth cohort is necessary for the trial.

What is Pritumumab and how does it work?

Pritumumab (PTB) is a monoclonal antibody that targets vimentin on cancer cells, allowing for selective treatment without damaging healthy tissue.